About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 675906, 12 pages
http://dx.doi.org/10.1155/2013/675906
Review Article

Add-On Effect of Chinese Herbal Medicine on Mortality in Myocardial Infarction: Systematic Review and Meta-Analysis of Randomized Controlled Trials

1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
2Chinese Medicine Department, Hong Kong Hospital Authority, Hong Kong

Received 31 August 2012; Accepted 16 November 2012

Academic Editor: Vassya Bankova

Copyright © 2013 Vincent C. H. Chung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. Wakai, “Myocardial infarction (ST-elevation),” BMJ Clinical Evidence, no. 202, article 01, 2011.
  2. A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. Murray, “Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data,” Lancet, vol. 367, no. 9524, pp. 1747–1757, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Unverzagt, K. Hirsch, M. Buerke, et al., “Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome (Protocol),” Cochrane Database of Systematic Reviews, no. 2, Article ID CD009669, 2012.
  4. J. L. Tang, B. Y. Liu, and K. W. Ma, “Traditional Chinese medicine,” The Lancet, vol. 372, no. 9654, pp. 1938–1940, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Xu and Y. Yang, “Traditional Chinese medicine in the Chinese health care system,” Health Policy, vol. 90, no. 2-3, pp. 133–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Shang, J. Chen, J. Zhang et al., “Three therapeutic tendencies for secondary prevention of myocardial infarction and possible role of Chinese traditional patent medicine: viewpoint of evidence-based medicine,” Journal of Evidence-Based Medicine, vol. 2, no. 2, pp. 84–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Zhang, Y. Yang, Y. Wang, and X. Gao, “Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury,” Pharmazie, vol. 66, no. 2, pp. 144–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Jiang, W. Dai, S. Yan, et al., “Biomarkers in the early period of acute myocardial infarction in rat serum and protective effects of Shexiang Baoxin Pill using a metabolomic method,” Journal of Ethnopharmacology, vol. 138, no. 2, pp. 530–536, 2011.
  9. Y. T. Cheng, Y. J. Yang, H. T. Zhang et al., “Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism,” Chinese Medical Journal, vol. 122, no. 13, pp. 1529–1538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Xu, C. Qiu, W. Wang et al., “HPLC/MS/MS for quantification of two types of neurotransmitters in rat brain and application: myocardial ischemia and protection of Sheng-Mai-San,” Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 1, pp. 101–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Wang, S. Minatoguchi, Y. Uno et al., “Treatment with sheng-mai-san reduces myocardial infarct size through activation of protein kinase C and opening of mitochondrial KATP channel,” American Journal of Chinese Medicine, vol. 29, no. 2, pp. 367–375, 2001. View at Scopus
  12. R. D. Riley, J. P. Higgins, and J. J. Deeks, “Interpretation of random effects meta-analyses,” British Medical Journal, vol. 342, article d549, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Shang, K. Huwiler, L. Nartey, P. Jüni, and M. Egger, “Placebo-controlled trials of Chinese herbal medicine and conventional medicine—Comparative study,” International Journal of Epidemiology, vol. 36, no. 5, pp. 1086–1092, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Wood, M. Egger, L. L. Gluud et al., “Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study,” British Medical Journal, vol. 336, no. 7644, pp. 601–605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Hrobjartsson, A. S. Thomsen, F. Emanuelsson, et al., “Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors,” British Medical Journal, vol. 344, article e1119, 2012.
  16. “Chinese pharmacopoeia online,” Chinese Pharmacopoeia Comission, http://www.chp.org.cn/cms/home/.
  17. J. P. T. Higgins, D. G. Altman, P. C. Gøtzsche, et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” British Medical Journal, vol. 343, article d5928, 2011.
  18. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity,” Statistics in Medicine, vol. 26, no. 25, pp. 4544–4562, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Scopus
  20. “Investigating heterogeneity,” in Cochrane Handbook for Systematic Reviews of Interventions, J. P. T. Higgins and S. Green, Eds., chapter 9.6, The Cochrane Collaboration, 2011.
  21. CHD Group of Guang'anmen Hospital, “Comparison of treatments with combined Traditional Chinese and western medicine or western medicine alone for acute myocardial infarction: 276 cases analysis,” Chinese Journal of Integrative Medicine, vol. 1, no. 1, pp. 10–12, 1981.
  22. W. Kou, Z. Chen, S. Tao, et al., “A randomized controlled trials on 268 patients with acute myocardial infarction treated with Yiqihuoxue injection,” Chinese Journal of Integrative Medicine, vol. 3, no. 3, pp. 146–148, 1983.
  23. K. Chen, Z. Qian, and Q. Dong, “A randomized controlled trials on 224 patients with acute myocardial infarction treated with Yiqihuoxue injection,” Chinese Journal of Integrative Medicine, vol. 4, no. 7, article 416, 1984.
  24. S. Liang, “Clinical observation of dehydrocorydalineon acute myocardial infarction,” Tianjin Journal of Traditional Chinese Medicine, no. 4, pp. 3–7, 1989.
  25. X. Xia, “Combined Dushentang and Thrombolytic therapy in the treatment of acute myocardial infarction,” Journal of Jiamusi Medical College, vol. 16, no. 2, pp. 32–33, 1993.
  26. C. Li and S. Zhang, “Combined traditional Chinese and western medicine in the treatment of acute myocardial infarction with cardiogenic shock,” Chinese Critical Care Medicine, vol. 6, no. 6, pp. 355–358, 1994.
  27. S. Li and F. Li, “Clinical observation of Huangqi and Glucose-insulin-potassium on 18 patients with acute myocardial infarction,” Chinese Journal of Integrative Medicine, vol. 14, no. 6, article 359, 1994.
  28. G. Yang, Q. Pang, Y. Peng, K. Wang, and S. Xing, “Influence of Shexiang Baoxin Wan on survival rate after acute myocardial infarction,” Shanghai Medical & Pharmaceutical Journal, no. 8, pp. 21–22, 1997.
  29. R. Zhang, C. Tu, Y. Yang, Y. Zhao, and X. Wu, “Tradition Chinese medicine (TCM) diagnostic system and clinical observation of Jianxinpian on myocardial infarction,” Tianjin Journal of Traditional Chinese Medicine, vol. 15, no. 4, pp. 160–162, 1998.
  30. S. Guo and Y. Zhang, “Clinical Study on the therapeutic effect of shenmai injection against myocardium stunning in thrombolytic therapy with urokinase for acute myocardialnfarction,” Acta Academiae Medicinae Weifang, vol. 21, no. 4, pp. 271–273, 1999.
  31. G. Li, W. Qi, K. Xiong, and X. G. H. Yang, “Clinical observation on 51 patients of acute myocardial infarction treated with thrombolytic therapy combined with Chinese herbal medicine,” Chinese Journal of Integrative Medicine, vol. 19, no. 8, pp. 461–462, 1999. View at Scopus
  32. D. Zhang, B. Tang, N. Xu, R. Yang, B. Chang, and J. Yan, “Clinical observation of combined traditional Chinese and western medicine on 52 patients with acute myocardial infarction,” Beijing Journal of Traditional Chinese Medicine, vol. 18, no. 5, pp. 16–17, 1999.
  33. S. Guo and Y. Zhang, “Clinical study on the therapeutic effect of suxiaojiuxinwan against myocardium stunning in thrombolytic therapy with urokinase for acute myocardial infarction,” Tianjin Pharmacy, vol. 12, pp. 1–3, 2000.
  34. G. Han, Z. Ma, X. Xue, et al., “Influences of astragulas injection on reperfusion injury of intravenous thrombolytic therapy in patients with acute myocardial infarction,” Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, vol. 7, no. 2, pp. 107–108, 2000.
  35. J. Li and B. Chen, “Effect of Zhubitang in acute myocardial infarction,” Journal of Emergency in Traditional Chinese Medicine, vol. 9, no. 2, pp. 50–51, 2000.
  36. Q. Li, C. Huang, X. Pan, and Z. Li, “Influence of SuxiaojiuxinWan on survival rate after acute myocardial infarction,” Tianjin Pharmacy, vol. 12, pp. 12–13, 2000.
  37. J. Lu, Y. Chen, J. Liang, Q. Yang, C. Li, and X. Yang, “Clinical observation on treatment with leech injection for acute myocardial infarction,” Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, vol. 7, no. 3, pp. 152–154, 2000.
  38. K. Yin, Y. Luo, T. Liu, X. Zou, and G. Mei, “Clinical observation of combined intravenous thrombolytic therapy and traditional Chinese medicine on 28 patients with acute myocardial infarction,” Journal of Emergency in Traditional Chinese Medicine, vol. 9, no. 3, pp. 89–90, 2000.
  39. G. Wu, N. Li, S. Bai, and J. Zhang, “Study on the treatment effect of Huangqi Danshen injection in treating acute myocardial infarction,” Journal of Clinical Cardiology, vol. 17, no. 2, article 91, 2001.
  40. Y. Bai, Y. Wang, Y. Hao, Y. Liang, X. Li, and B. Qian, “Clinical observation of 999 Shenmai injection and western medicine on 62 patients with acute myocardial infarction,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 11, no. 4, pp. 285–286, 2002.
  41. J. Shi, X. Zhang, and W. Sun, “Complementary effect of Dengzhanhuasu on acute myocardial infarction,” Chinese Journal of Integrative Medicine, vol. 22, no. 3, pp. 227–228, 2002.
  42. Y. Guan and J. Guan, “Influence of Xingding injection on the prognosis after acute myocardial infarction and hemorrheology,” Liaoning Journal of Traditional Chinese Medicine, vol. 30, no. 2, article 122, 2003.
  43. S. Zhang, Y. Liu, and X. Wang, “Combined traditional Chinese and western medicine on 45 patients with acute myocardial infarction,” Journal of Practical Traditional Chinese Internal Medicine, vol. 17, no. 3, article 186, 2003.
  44. G. Han, T. Wang, Z. Bai, Q. Wang, and B. Yang, “Influence of Shexiang Baoxin Wan on reperfusion injury after thrombolytic therapy in acute myocardial infarction,” Chinese Traditional Patent Medicine, vol. 26, pp. 30–31, 2004.
  45. X. Li, W. Zhang, Z. Wang, et al., “Clinical observation of Shexiang Baoxin Wan on acute myocardial infarction,” Chinese Traditional Patent Medicine, vol. 26, pp. 32–34, 2004.
  46. S. Liu, Y. Liu, and Y. Wang, “Study of effect of Shenmai injection on acute myocardial infarction,” China Journal of Modern Medicine, vol. 14, no. 5, pp. 108–109, 2004.
  47. G. Yang, C. Li, and A. Tang, “Study on treatment effect of astragalus injection combined thrombolytic therapy on ischemia/reperfusion injury in acute myocardial infarction,” Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, vol. 11, no. 3, pp. 162–164, 2004.
  48. L. Chen, H. Zhang, X. Zheng, and A. Wang, “Influence of Huangqi injection on cardiovascular events after thrombolytic therapy,” Chinese Journal of Integrative Medicine, vol. 14, no. 10, article 1288, 2005.
  49. Y. Deng, X. Chen, and J. Liu, “Clinical observation of Xingnaojing injection on acute myocardial infarction,” Journal of Emergency in Traditional Chinese Medicine, vol. 14, no. 12, pp. 1179–1180, 2005.
  50. Y. He, J. Chen, and J. Liang, “The clinical observation on kaixin capsule for ischemical reperfusion injury after acute myocardial infarction, the syndrome of blood stasis due to deficiency of Qi in TCM,” Journal of Emergency in Traditional Chinese Medicine, vol. 14, no. 12, pp. 1137–1139, 2005.
  51. H. Li, “Anti-myocardial ischemia effect of Di’aohuangqi injection in acute myocardial infarction,” Chinese Journal of Practical Medicine, vol. 32, no. 7, article 49, 2005.
  52. Y. Liu, “Combined thrombolytic therapy and tradition Chinese medicine (TCM) syndrome differentiation in the treatment of acute myocardial infarction,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 14, no. 6, pp. 733–734, 2005.
  53. Y. Miao, F. Chen, and M. Ma, “Prevention effect of Shengmai injection in reperfusion injury after urokinase thrombolytic therapy on patients with acute myocardial infarction,” Chinese Medicine of Factory and Mine, vol. 18, no. 4, pp. 363–364, 2005.
  54. Y. Yang, Y. Ye, and L. Mao, “Influence of Shexiang Baoxin Wan on ventricular structure and function after acute myocardial infarction,” Journal of the Practical Chinese With Modern Medicine, vol. 18, no. 11, pp. 1583–1584, 2005.
  55. L. Ding and M. Xu, “The complementary effect of Shenmai injection in treating acute myocardial infarction complicated by cardiogenic shock Gansu,” Journal of Traditional Chinese Medicine, vol. 19, no. 8, article 11, 2006.
  56. B. M. Du, Z. L. Lu, Z. Chen, Y. F. Wu, W. D. Zhao, and T. G. Huang, “China coronary secondary prevention study: analysis of patients with different myocardial infarction history,” Chinese Journal of Internal Medicine, vol. 45, no. 1, pp. 21–24, 2006. View at Scopus
  57. Z. E. Li, “Clinical research on effects of shenfu injection in different dosage in preventing heart failure occurred in patients of acute myocardial infarction with elevated ST segment,” Chinese Journal of Integrative Medicine, vol. 26, no. 6, pp. 555–557, 2006. View at Scopus
  58. L. Ma, D. Shi, J. Liu, L. Ma, X. Zhu, and K. Meng, “Influence of Yuxingeng fluid on left ventricular function after acute myocardiac infarction,” Chinese Journal of Integrative Medicine, vol. 26, no. 2, pp. 167–168, 2006.
  59. H. Qi, X. Zhao, and Y. Li, “The effect of Sodium tanshinone IIA sulfonate (STS) injection in treating acute myocardiac infarction (AMI),” China Medical Herald, vol. 3, no. 23, pp. 22–24, 2006.
  60. Y. Shen, H. Gao, and G. Ruan, “Clinical observation of Shenfu injection on acute myocardiac infarction,” Journal of Qiqihar Medical College, vol. 27, no. 9, pp. 1038–1039, 2006.
  61. S. Wang and Y. Guo, “Clinical observation of Shenmai injection on acute myocardiac infarction,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 13, no. 6, pp. 64–65, 2006.
  62. X. Wei, “Clinical observation of combined thrombolytic therapy and Shenfu injection for ischemical reperfusion injury,” Journal of Emergency in Traditional Chinese Medicine, vol. 15, no. 8, pp. 866–867, 2006.
  63. J. Wu and W. Wu, “Clinical observation of shenmai injection for reperfusion injury after intravenous thrombolysis on 30 patients with acute myocardial infarction,” Nei Mongol Journal of Traditional Chinese Medicine, vol. 25, no. 3, article 8, 2006.
  64. J. Yang, J. Li, L. Zhang, L. Song, and P. Han, “Secondary prevention effect of xuezhikang on coronary heart disease,” Chinese Circulation Journal, vol. 21, no. 4, pp. 276–278, 2006.
  65. H. Chen, S. Cai, C. Hong, X. Liu, and Z. Wong, “Clinical observation of Tongxinluo capsule on acute myocardiac infarction,” Journal of Emergency in Traditional Chinese Medicine, vol. 16, no. 7, pp. 823–824, 2007.
  66. Z. Li, W. Zheng, and H. Wu, “Influence of Guanxinning injection on left ventricular remodeling after acute myocardial infarction,” Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, vol. 14, no. 4, pp. 227–230, 2007.
  67. C. Liang, “Clinical observation on 90 patient of acute myocardiac infarction treated with combined traditional Chinese and western medicine,” Journal of Practical Traditional Chinese Internal Medicine, vol. 21, no. 6, pp. 55–56, 2007.
  68. G. Pan, F. Xu, X. Xu, X. Feng, and Z. Hu, “Clinic observation of tongxinluo capsule in conservative treatment of patients with AMI,” Progress in Modern Biomedicine, vol. 7, no. 6, article 957, 2007.
  69. Y. Zhai, “Effect of Shenmai injection on QT dispersion in patients with acute myocardiac infarction,” Chinese Journal of Integrative Medicine, vol. 16, no. 7, pp. 916–917, 2007.
  70. Y. Ding and W. Dong, “Clinical observation of Shenmai injection in the treatment of elder patients with acute myocardiac infarction,” Chinese Community Doctors, vol. 10, no. 23, article 129, 2008.
  71. J. Lan, “The influence of Xinmaitong capsule on heart rate variability in patients with acute myocardiac infarction,” Chinese Journal of the Practical Chinese With Modern Medicine, vol. 21, no. 14, pp. 1187–1189, 2008.
  72. C. Yu and C. Li, “Clinical observation on angina pectoris after intravenous thrombolysis in acute myocardial infarction treated with combination of TCM and western medicine,” Journal of Practical Traditional Chinese Medicine, vol. 24, no. 9, pp. 579–580, 2008.
  73. T. Yu and M. Zhu, “Clinical observation on 32 patients of acute myocardiac infarction treated with combination of Yinxingdamo injection and intravenous thrombolytic therapy,” Journal of New Chinese Medicine, vol. 40, no. 10, pp. 41–43, 2008.
  74. J. Zhang, “Clinical observation of Shuxuening and Shenmai injection on acute myocardiac infarction,” China Medical Herald, vol. 5, no. 8, pp. 68–69, 2008.
  75. Z. Gao, “Clinical Effects of Danhong Injecta on complications of Acute Myocardial Infarction,” China Medical Herald, vol. 11, no. 4, article 582, 2009.
  76. H. Lin, I. Yang, and D. Zheng, “Clinical observation on the routine and Compound Danshen Dropping Pills in the treatment of patients with acute myocardial infarction,” China Medical Herald, vol. 6, no. 25, pp. 52–53, 2009.
  77. P. Liu, Y. Zhang, J. Tang, and H. Li, “The effect and clinical significance of tanshinone injection on plasma NT-proBNP in acute myocardial infarction,” Chinese Journal of Difficult and Complicated Cases, vol. 8, no. 6, pp. 327–329, 2009.
  78. X. Song, N. Gao, and J. Zou, “Thirty-six cases of acute inferior myocardial infarction complicated by right ventricular infarction by integrative treatment,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 7, no. 5, pp. 516–517, 2009.
  79. X. Yuan, “Clinical observation of combined intravenous thrombolytic therapy and Shenmai injection on acute myocardiac infarction treated,” China Modern Medicine, vol. 16, no. 10, article 56, 2009.
  80. Q. Zhao and Q. Wei, “The complementary effect of Tongxinluo capsule on acute myocardiac infarction,” Chinese Journal of Integrative Medicine, vol. 18, no. 13, article 1507, 2009.
  81. Y. Zuo, R. Jia, and D. Yu, “The influence and therapeutic effect of Dengzhanhuasu on the high-sensitivity C-reactive protein of patients with acute myocardial infarction,” Clinical Medicine of China, vol. 25, no. 3, pp. 291–293, 2009.
  82. H. Guo, “Clinical observation on anti-myocardial ischemia activity after acute myocardiac infarction treated with Fufangdanshenpian,” Chinese Journal of Ethnomedicine and Ethnopharmacy, no. 1, article 142, 2010.
  83. Q. Xu and Q. Xiong, “Combined traditional Chinese and western medicine in the treatment of acute myocardiac infarction,” Hubei Journal of Traditional Chinese Medicine, vol. 32, no. 3, pp. 20–22, 2010.
  84. E. Rapaport, R. Bernard, and E. Corday, “Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the joint International Society and Federation of Cardiology/World Health Organization Task Force on standardization of clinical nomenclature,” Circulation, vol. 59, no. 3, pp. 607–609, 1979. View at Scopus
  85. Chinese Society of Cardiology, “AMI guidelines for diagnosis and treatment,” Chinese Journal of Cardiology, vol. 29, no. 12, pp. 710–725, 2001.
  86. F. Van De Werf, D. Ardissino, A. Betriu et al., “Treatment of acute myocardial infarction in patients with ST segment elevation at onset of symptoms: the task force on the management of acute myocardial infarction of the European Society of Cardiology,” Italian Heart Journal Supplement, vol. 4, no. 12, pp. 981–1016, 2003. View at Scopus
  87. A. Shang, K. Huwiler, L. Nartey, P. Jüni, and M. Egger, “Placebo-controlled trials of Chinese herbal medicine and conventional medicine—Comparative Study,” International Journal of Epidemiology, vol. 36, no. 5, pp. 1086–1092, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Luo and H. Xu, “Outcome measures of Chinese Herbal Medicine for Coronary Heart Disease: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 927392, 9 pages, 2012.
  89. L. Wood, M. Egger, L. L. Gluud et al., “Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study,” British Medical Journal, vol. 336, no. 7644, pp. 601–605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Hróbjartsson, A. S. S. Thomsen, F. Emanuelsson, et al., “Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors,” British Medical Journal, vol. 344, article e1119, 2012.